Shire Wins U.S. Court Ruling Upholding Patents on Vyvanse

Shire Plc (SHP) won a U.S. court ruling blocking generic versions of its best-selling product, the Vyvanse treatment for attention deficit hyperactivity disorder.

U.S. District Judge Stanley R. Chesler in New Jersey found that Shire’s patents on the drug are valid and would be infringed if five generic-drug companies introduced copies of the medicine, Shire said in a statement today.

Unless the generic companies win an appeal, they will be blocked from introducing a copy of the drug until the patents expire in 2023, Dublin-based Shire said. Shire sued the companies after they filed for approval from the U.S. Food and Drug Administration to make copies of Vyvanse.

The generic companies sued by Shire are Actavis Plc (ACT), Amneal Pharmaceuticals LLC, Mylan Inc. (MYL), Roxane Laboratories Inc., and Novartis AG (NOVN)’s Sandoz Inc.

Vyvanse had sales of $1.2 billion last year. Shire is the subject of an unsolicited, 27.3 billion-pound ($46.4 billion) takeover proposal from AbbVie Inc. (ABBV)

Shire shares rose 0.7 percent to 44.33 pounds at 8:18 a.m. in London.

To contact the reporter on this story: Phil Serafino in Paris at pserafino@bloomberg.net

To contact the editors responsible for this story: Jacqueline Simmons at jackiem@bloomberg.net Kim McLaughlin, Thomas Mulier

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.